Cancer Research UK
Therapeutic Catalyst - Early Therapy Award
Further cut-offs expected preceding February and June 2027 review rounds
Last updated:
Therapeutic Catalyst, Early Therapy Award funds academic researchers worldwide to advance hit identification, druggability assessment, and early therapeutic development for adult cancers using antibody and small molecule approaches. Grants of up to £350,000 cover 18-24 months and are delivered in collaboration with Cancer Research Horizons, the commercialisation arm of Cancer Research UK. The call targets researchers with independent labs seeking to bridge basic discovery and translational development.
Details
| Funder | Cancer Research UK |
| Budget | Up to £350k |
| Deadline | 25 September 2026 |
| Duration | 18-24 months |
| Consortium | No - individual applicant, project run collaboratively with Cancer Research Horizons drug discovery team |
| Application | 2-stage: expression of interest → full proposal |
| Frequency | 3 times per year |
| Next round | 2027-02 |
| Eligible countries | GB |
Eligibility & scope
Funds hit identification, druggability assessment and early therapeutic project development for adult cancers using antibody or small molecule approaches. Run collaboratively with Cancer Research Horizons; open to academic researchers worldwide.
Who Should Apply
- •Academic researchers with an independent laboratory
- •Investigators focused on hit identification, druggability assessment, or early therapeutic development
- •Projects targeting adult cancers using antibody or small molecule chemistry
- •Teams willing to embed commercialisation-focused collaboration with Cancer Research Horizons
Key Dates
- •Expression of interest deadline: 25 September 2026
- •Two-stage process: shortlisted candidates invited to submit full proposal
- •Project duration: 18-24 months
Tips for Applicants
- ✓Cancer Research Horizons collaboration is embedded in the award structure, frame your project with clear translation and IP milestones that signal commercial viability.
- ✓Hit identification and druggability assessment are core themes; proposals anchored to target validation and feasibility demonstration score higher than exploratory basic research.
- ✓If US-based, note that indirect cost recovery caps at 10%; budget your full institutional overhead separately or find co-funding.
Frequently Asked Questions
What is the budget for the Therapeutic Catalyst, Early Therapy Award?
Up to £350,000 per project covering 18-24 months of work.
Who is eligible for Therapeutic Catalyst?
Academic researchers worldwide who hold an independent laboratory and are pursuing hit identification, druggability assessment, or early therapeutic development in adult cancer.
What does Cancer Research Horizons do in this award?
Cancer Research Horizons, the commercialisation arm of Cancer Research UK, works collaboratively with award holders to support translation toward therapeutic development and IP management.
Is Therapeutic Catalyst a two-stage application?
Yes, applicants first submit an expression of interest; successful applicants are then invited to submit a full proposal.
Summary generated by AI based on published grant information. Always verify details on the funder's website.
Similar grants
Therapeutic Catalyst
Cancer Research UKDeadline: 25 Sept 2026Up to £250k (Target Award) or up to £350k (Early Therapy Award)Therapeutic Catalyst - Target Award
Cancer Research UKDeadline: 25 Sept 2026Up to £250kChildhood Cancer Therapeutic Catalyst
Cancer Research UKUp to £250kDrug Development Project
Cancer Research UKDiscovery Programme Award
Cancer Research UKDeadline: 29 Sept 2026Up to £2.5m
Browse Related
Could Therapeutic Catalyst - Early Therapy Award be right for you?
Deadline in 12 days. See your personalised match score for this grant and others in 30 seconds. No signup needed to preview.
See my matches free →